FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
21/07/2026
Voltar para busca
Dado oficial do USPTO
KNOTBODY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
KNOTBODY
ST13
US500000079430782Classe
1, 5, 42, 44
Pedido
79430782
Registro
8217622
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
19
Atualização mais recente
21/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
23/06/2025
Data de registro
21/04/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/04/2026
Última transação
21/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
TRUSILO, KELLY JEAN
Unidade examinadora
L70
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Maxion Therapeutics Limited
Representantes
Ben Natter Haug Partners, LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in industry and science; biochemicalspolypeptides and engineered antibodies for scientificlaboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating or G-protein-coupled receptor modulating engineered antibodiesincluding antagonists or agonists for scientificlaboratory or research purposes; ion channel modulating or G-protein-coupled receptor modulating engineered antibodiesincluding antagonists or agonists for use in the manufacture of pharmaceuticals and drugs; engineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) for scientificlaboratory or research purposes; engineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientificlaboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs
Classe 5
Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activityincluding preparations for the prevention and treatment of painautoimmunitycardiovascular disease and cancer; drugs for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activityincluding preparations for the prevention and treatment of painautoimmunitycardiovascular disease and cancer; engineered antibodies for medical use; pharmaceuticalsdrugs and pharmaceutical preparations incorporating engineered antibodiesion channel modulating engineered antibodies including antagonists or agonistsengineered antibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or engineered antibodies derived from mini-protein toxins for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activityincluding those for the prevention and treatment of painautoimmunitycardiovascular disease and cancer; vaccines
Classe 42
Scientific and technological services namely scientific researchanalysis and testing in the fields of pharmaceuticalsbiochemicalspolypeptidesantibodiesion channel modulating or G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; scientific and medical research laboratory services relating to the production of antibodiesion channel modulating antibodies including antagonists or agonistsantibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discoverypreclinical and clinical development of therapeutic products; informationadvisory and consultancy services in relation to all of the aforesaid
Classe 44
Medical services; medical testinganalysis and diagnostic services in the field of antibodies; medical services connected with the treatment of diseases through the use of antibodiesion channel modulating antibodies including antagonists or agonistsantibodies being antagonists or agonists for modulating G-protein-coupled receptors (GPCRs) or antibodies derived from mini-protein toxinspharmaceuticalsdrugs and pharmaceutical preparations derived from the aforesaid; informationadvisory and consultancy services in relation to all of the aforesaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
19 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
21/04/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
21/04/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/03/2026
PUBO
PUBLISHED FOR OPPOSITION
03/03/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
25/02/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/02/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/02/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/02/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/02/2026
RFNT
REFUSAL PROCESSED BY IB
01/01/2026
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
18/12/2025
RFRR
REFUSAL PROCESSED BY MPU
18/12/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/11/2025
CNRT
NON-FINAL ACTION WRITTEN
11/11/2025
DOCK
ASSIGNED TO EXAMINER
10/11/2025
MAFR
APPLICATION FILING RECEIPT MAILED
25/08/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/08/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/08/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KNOTBODY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.